It has been reported that LPA1 activation increases nuclear factor erythroid 2-related factor 2 (Nrf2) stability, with subsequent increases in multidrug-resistant transporters and antioxidant genes that protect breast cancer cells from doxorubicin-induced death [127]. The gene discussed is NFE2L2; the disease is breast cancer.